Table 2.
Risk factors for anon-compliance to bisphosphonates in patients with rheumatoid arthritis
| Variables | Univariable | Multivariable | ||
|---|---|---|---|---|
| OR (95% CI) | p value | bOR (95% CI) | p value | |
| Dosing frequency weekly vs. monthly BPs | 2.42 (1.57–3.73) | <0.001 | 2.48 (1.59–3.89) | <0.001 |
| Seropositive RA | 0.43 (0.26–0.73) | 0.002 | 0.51 (0.29–0.89) | 0.019 |
| Disease duration ≥ 24 months | 0.48 (0.31–0.73) | 0.001 | 0.66 (0.41–1.05) | 0.077 |
| Calcium /vitamin D supplement | 2.01 (1.21–3.34) | 0.007 | 1.8 (1.04–3.12) | 0.037 |
| Previous compression fracture | 0.9 (0.42–1.97) | 0.8 | ||
| Reimbursement for BPs | 1.15 (0.75–1.15) | 0.519 | - | - |
| Age, years | 1 (0.99–1.02) | 0.632 | - | - |
| Glucocorticoids use | 0.79 (0.44–1.42) | 0.427 | ||
| Baseline DEXA | 0.68 (0.35–1.29) | 0.236 | ||
| DAS28-ESR | 1.05 (0.92–1.19) | 0.477 | ||
BPs bisphosphonates, RA rheumatoid arthritis, DEXA dual energy X-ray absorptiometry, DAS28-ESR disease activity score assessed using the 28-joint count for swelling and tenderness- erythrocyte sedimentation rate
aNon-compliance was defined if the 1-year medication possession ratio was less than 0.8
bEstimated using multivariable backward logistic regression models including dosing frequency of BPs, seropositive RA, disease duration > 24 months, calcium /vitamin D supplement, age and reimbursement for BPs